The pharmaceutical community is buzzing with anticipation retatrutide and anxiety surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some current weight loss solutions, retatrutide appears to provide a significant substantial decrease in body size and i